The mRNA vaccine manufacturers continue to have a very strong position in price negotiations.
(Photo: dpa)
Frankfurt Continued high vaccine demand and market share gains compared to competitors from China should bring the leading Covid vaccine manufacturers Biontech / Pfizer and Moderna very high, possibly even strongly growing, sales in 2022.
A number of analysts and market observers are now assuming this. The British analysis company Airfinity, which is following the events in the Covid area particularly closely, even trusts the two mRNA specialists that they will almost double the revenues with their Covid vaccines again in the coming year.
According to an analysis published earlier this week, Pfizer and Biontech are likely to increase their sales of the Comirnaty vaccine by three quarters to more than 54 billion dollars, and Moderna will then grow by 120 percent to almost 39 billion dollars in the coming year.
Read on now
Get access to this and every other article in the
Web and in our app for 4 weeks free of charge.
Further
Read on now
Get access to this and every other article in the
Web and in our app for 4 weeks free of charge.
Further